Bayer HealthCare Nexavar Access Program
In 2007, Bayer HealthCare, in partnership with local authorities and charitable organizations, started the first patient access program for Nexavar (sorafenib) in Asia for the treatment of renal cell carcinoma and is planning further implementation in this region. Bayer HealthCare donates its medicine Nexavar to facilitate access for patients who cannot afford the cost of a full course of therapy. In 2008, Bayer HealthCare initiated another patient access program for Nexavar, for the treatment of hepatocellular carcinoma, after its approval for this indication. After a patient is diagnosed with renal cell or hepatocellular carcinoma carcinoma, he or she is referred to a specialist center, which evaluates the patient's eligibility for participation in the facilitated access program. If they are eligible for assistance, based on their financial situation, the patient will receive the medicine free-of-charge, either immediately or after an initial period of treatment.